Clinical trials
HER2 Positive Breast Carcinoma clinical trials
Below are recruiting her2 positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 278 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Denver, ColoradoAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Jonesboro, ArkansasAges 18 years+ - NCT06414733RecruitingPhase 1
Vaccine for advanced breast or esophageal cancer
This trial tests a vaccine that targets HER2 protein on cancer cells. It is for people with advanced breast or esophageal cancer whose tumors have certain markers. The vaccine may help your immune system fight the cancer.
Indianpolis, IndianaAges 18 years+ - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+ - NCT06891833RecruitingPhase 2/Phase 3
New drug combo for HER2-positive breast cancer before surgery
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Bengbu, AnhuiAges 18–75 - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT07631052RecruitingPhase 2
Low-dose Capecitabine for High-risk Early Breast Cancer
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Toronto, OntarioAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Hot Springs, ArkansasAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06525766RecruitingPhase 2
Adaptive capecitabine therapy for metastatic ER+ HER2− breast cancer
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
Scottsdale, ArizonaAges 18 years+ - NCT05327608RecruitingPhase 2
Time-restricted eating during breast cancer chemotherapy
This study is testing whether time-restricted eating (confining all meals to a specific window each day) can improve the response to chemotherapy in women with newly diagnosed breast cancer. Participants will follow this eating pattern for 16 weeks while receiving their standard chemotherapy, and the researchers will monitor how the tumor shrinks.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05893966Recruiting
Tested extra radiation to the tumor area in HER2-positive breast cancer
This study follows people with HER2-positive invasive breast cancer to see how adding radiation to the tumor bed may affect outcomes. It may be most relevant if you are scheduled for breast radiation and have not had radiation to the same side before.
Seoul, SeoulAges 19 years+ - NCT05512364RecruitingPhase 3
Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
AnderlechtAges 18 years+ - NCT05306041RecruitingPhase 2
Pre-surgery hormone therapy with or without PI3K inhibitor
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT07043725RecruitingPhase 3
Neoadjuvant TQB2102 for HER2-positive breast cancer
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Bengbu, AnhuiAges 18–75 - NCT06830889RecruitingPhase 3
BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy
This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06534125Recruiting
Acupuncture to prevent joint pain from hormone therapy in Black women
This study tests whether acupuncture can prevent joint pain caused by a common hormone therapy pill (aromatase inhibitor) in Black women who have finished treatment for early-stage breast cancer.
Atlanta, GeorgiaAges 18 years+
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
HER2 Positive Breast Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for her2 positive breast carcinoma?
- Yes. Clin2 currently lists 278 recruiting her2 positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.